Qual é a influência da microbiota na obesidade e em seu quadro inflamatório? / What is the influence of microbiota on obesity and its inflammatory involvement?

A obesidade tem causa multifatorial que atinge atualmente mais da metade da população brasileira. Mais recentemente, a microbiota intestinal foi considerada um fator que contribui para essa condição. Os objetivos deste estudo foram revisar a influência da microbiota intestinal na obesidade e no processo inflamatório, e analisar os efeitos da utilização dos pré e probióticos. Foi realizada revisão sistemática sobre o assunto. Dos mais de 27.000 artigos, apenas 16 respeitaram os critérios de inclusão. Em conclusão, o desequilíbrio da microbiota aparece como fator favorável ao desenvolvimento da obesidade e do quadro inflamatório decorrente dela. Tanto o uso de prebióticos quanto probióticos são recursos válidos no tratamento da obesidade, porém os primeiros parecem proporcionar melhor qualidade de vida.

Obesity has a multifactorial etiological condition that involves more than half of the Brazilian population. More recently, the intestinal microbiota was considered a factor that contributes to this condition. The aims of this study were to review the intestinal microbiota influence in the obesity and in the inflammatory response, and to analyze the effects of using prebiotic and probiotic medications. A systematic review was firstly done. More than 27,000 articles were found, but only 16 contained the proper criteria. In conclusion, the microbiota imbalance seems to increase the obesity development and its inflammatory aspects. Both the use of pre and probiotics are good options in the obesity treatment, though the first ones seem to enhance bettere quality of life.

Effects of in feed removal of antimicrobials in comparison to other prophylactic alternatives in growing and finishing pigs / [Efeitos na remoção de antimicrobianos na ração em comparação a alternativas profiláticas em suínos nas fases de crescimento e de terminação]

The utilization of antimicrobials in animal production, causes selection of resistant bacteria. The objective of this study was to compare the utilization of alternatives in association with preventive antibiotic therapy in swine feed during the growing and finishing phases. 1,045 animals were used from 60 to 190 days of age and were subjected to six treatments with 16 repetitions as follows: 1) antibiotic free; 2) antibiotics; 3) prebiotic; 4) probiotic; 5) essential oils; and 6) organic acid. Animals were weighted, and clinical history was recorded including mortality and diarrhea. At the abattoir, pneumonia index and gastric ulcers were investigated. The cost for each treatment was discussed. No difference between treatments were observed (P>0.05) regarding feed conversion rate (2.64±0.03), overall average weight gain (107.06±0.9kg), average daily weight gain (856.49±7.7g) and carcass weight (92.4±0.7kg). The application injectable drugs in animals presenting clinical symptoms, represented US$ 0.56/intervention, without difference between the treatments (P>0.05). Furthermore, independently of the treatment, high frequency of pneumonia was observed (>0.90). No difference for the degree of gastric ulcer nor feces consistency were observed (P>0.05). The utilization of antibiotic therapy and alternatives to antibiotics in feed did not produce benefits to the production indices and sanitary performances of the animals.(AU)

A utilização de antimicrobianos na produção animal provoca seleção de bactérias resistentes. O objetivo do estudo foi comparar a utilização de alternativas associadas à antibioticoterapia preventiva na alimentação de suínos nas fases de recria e de terminação. Foram utilizados 1.045 animais de 60 a 190 dias de idade, submetidos a seis tratamentos com 16 repetições, como segue: 1) sem antibióticos; 2) com antibióticos; 3) prebióticos; 4) probióticos; 5) óleos essenciais; e 6) ácidos orgânicos. Os animais foram pesados, e a história clínica foi registrada, incluindo mortalidade e diarreia. No abatedouro, foram investigados índices de pneumonia e úlceras gástricas. O custo de cada tratamento foi discutido. Não houve diferença entre os tratamentos (P>0,05) em relação à taxa de conversão alimentar (2,64 ± 0,03), ao ganho de peso médio geral (107,06 ± 0,9kg), ao ganho de peso médio diário (856,49 ± 7,7g) e ao peso de carcaça (92,4 ± 0,7kg). A aplicação de medicamentos injetáveis em animais com quadro clínico representou US$ 0,56/intervenção, sem diferença entre os tratamentos (P>0,05). Além disso, independentemente do tratamento, foi observada alta frequência de pneumonia (>0,90). Não foi observada diferença para o grau de úlcera gástrica nem na consistência das fezes (P>0,05). A utilização de antibioticoterapia e de alternativas aos antibióticos na ração não trouxe benefícios aos desempenhos zootécnico e sanitário dos animais.(AU)

Probióticos y prebióticos: rol en la terapéutica de la enfermedad diarreica aguda infantil / Probiotics and prebiotics: its role in childhood acute diarrheal disease therapy

RESUMEN: La enfermedad diarreica aguda infantil (EDAI), constituye un problema de salud pública, representando la 2ª causa de morbimortalidad infantil en menores de 5 años, en el Ecuador. La hidratación oral y parenteral en los niños hospitalizados bajo normas de administración de conformidad con el grado de deshidratación y pérdida de peso, así como medidas preventivas como la vacunación obligatoria contra el rotavirus, han contribuido a disminuir, pero no a solucionar este problema de salud infantil. Múltiples factores contribuyen para que no se resuelva: socioeconómicos, educacionales, el destete temprano y malas prácticas alimenticias, entre otros. Últimos estudios han propuesto la utilización de probióticos que contribuyan a disminuir el problema sugieriendo el usode Saccharomyces boulardii (SB), asociado a un prebiótico; lo que permitiría acortar el tiempo de tratamiento de una EDAI; por lo que la simbiosis entre SB y un prebiótico denominado fructooligosacárido (FOS), podría ser una alternativa para reducir costos y complicaciones. Una alternativa para medir el curso clínico de una EDAI en infantes es la escala BITTS, de reciente creación y fácil aplicación por clínicos. El objetivo de este manuscrito fue resumir la evidencia existente respecto del rol de losprobióticos y prebióticos en la terapéutica de de la EDAI.

SUMMARY: In Ecuador childhood acute diarrheal disease (CADD) constitutes a serious public health problem, representing the 2nd cause of infant morbidity and mortality in children under 5 years of age. Oral and parenteral hydration in hospitalized children, with standard treatments according to their degree of dehydration and weight loss, as well as preventive measures such as mandatory vaccination against rotavirus, have contributed to a decrease. Nevertheless, this childhood disease has still not been resolved. There are multiple contributing factors involved that prevent complete eradication of the disease Among these are socio-economic problems, education, early weaning and poor feeding practices, all of which continue to affect infants. Recent studies have proposed the use of probiotics that help reduce the problem and it has been suggested that Saccharomyces boulardii (SB), associated with a prebiotic, would reduce the treatment time of an CADD. Therefore, the symbiosis between the SB probiotic and a prebiotic called fructo- oligosaccharide (FOS) could be an alternative to reduce complications and reduce costs. An alternative to measure the clinical course of an CADD in infants is the BITTS scale, which was recently created and can easily be applied by clinicians. The aim of this manuscript was to summarize the existing evidence regarding the role of PROBIOTICS and prebiotics in the treatment of CADD.

Enzymatic preparation of manno-oligosaccharides from locust bean gum and palm kernel cake, and investigations into its prebiotic activity

BACKGROUND: Manno-oligosaccharides (MOS) is known as a kind of prebiotics. Mannanase plays a key role for the degradation of mannan to produce MOS. In this study, the mannanases of glycoside hydrolase (GH) families 5 Man5HJ14 and GH26 ManAJB13 were employed to prepare MOS from locust bean gum (LBG) and palm kernel cake (PKC). The prebiotic activity and utilization of MOS were assessed in vitro using the probiotic Lactobacillus plantarum strain. RESULTS: Galactomannan from LBG was converted to MOS ranging in size from mannose up to mannoheptose by Man5HJ14 and ManAJB13. Mannoheptose was got from the hydrolysates produced by Man5HJ14, which mannohexaose was obtained from LBG hydrolyzed by ManAJB13. However, the same components of MOS ranging in size from mannose up to mannotetrose were observed between PKC hydrolyzed by the mannanases mentioned above. MOS stability was not affected by high-temperature and high-pressure condition at their natural pH. Based on in vitro growth study, all MOS from LBG and PKC was effective in promoting the growth of L. plantarum CICC 24202, with the strain preferring to use mannose to mannotriose, rather than above mannotetrose. CONCLUSIONS: The effect of mannanases and mannan difference on MOS composition was studied. All of MOS hydrolysates showed the stability in adversity condition and prebiotic activity of L. plantarum, which would have potential application in the biotechnological applications.

Probióticos y prebióticos: beneficios en dermatología / Probiotics and prebiotics: benefits in dermatology

La piel es el órgano más extenso del cuerpo humano, y constituye el límite físico entre el individuo y su entorno; a pesar de tener un sistema inmunológico funcional la piel está colonizada por diversos tipos de microorganismos, en su mayoría benéficos, que en conjunto componen el microbioma cutáneo, el cual juega un papel importante en la homeostasis corporal y su modificación está implicada en diversas patologías, lo que lo ha convertido en una potencial diana terapéutica. Los probióticos y prebióticos se han estudiado en afecciones inflamatorias de la piel como la dermatitis atópica, el acné, la dermatitis seborreica y el cáncer de piel. En esta revisión describimos a la luz de la evidencia actual su eficacia en dermatosis relacionadas con disbiosis cutánea.

The skin is the largest organ in the human body and constitutes the physical boundary between the individual and their environment; despite having a functional immune system, the skin is colonized by various types of microorganisms, mostly beneficial, which together constitute the skin microbiome, which plays an important role in body homeostasis and its modification is involved in various pathologies, which has made it a potential therapeutic target. Probiotics and prebiotics have been studied in inflammatory skin conditions such as atopic dermatitis, acne, seborrheic dermatitis, and skin cancer. In this review we describe its efficacy in dermatoses related to cutaneous dysbiosis in light of current evidence.

Microbe-based management for colorectal cancer / 中华医学杂志(英文版)

Colorectal cancer (CRC) is one of the most prevalent, most lethal cancers in the world. Increasing evidence suggests that the intestinal microbiota is closely related to the pathogenesis and prognosis of CRC. The normal microbiota plays an essential role in maintaining gut barrier function and the immune microenvironment. Recent studies have identified carcinogenic bacteria such as enterotoxigenic Bacteroides fragilis (ETBF) and Streptococcus gallolyticus (S. gallolyticus), as well as protective bacterial such as Akkermansia muciniphila (A. muciniphila), as potential targets of CRC treatment. Gut microbiota modulation aims to restore gut dysbiosis, regulate the intestinal immune system and prevent from pathogen invasion, all of which are beneficial for CRC prevention and prognosis. The utility of probiotics, prebiotics, postbiotics, fecal microbiota transplantation and dietary inventions to treat CRC makes them novel microbe-based management tools. In this review, we describe the mechanisms involved in bacteria-derived colorectal carcinogenesis and summarized novel bacteria-related therapies for CRC. In summary, we hope to facilitate clinical applications of intestinal bacteria for preventing and treating CRC.

A novel supplement with yeast β-glucan, prebiotic, minerals and Silybum marianum synergistically modulates metabolic and inflammatory pathways and improves steatosis in obese mice / 中西医结合学报

OBJECTIVE@#To evaluate the synergic effects of a novel oral supplement formulation, containing prebiotics, yeast β-glucans, minerals and silymarin (Silybum marianum), on lipid and glycidic metabolism, inflammatory and mitochondrial proteins of the liver, in control and high-fat diet-induced obese mice.@*METHODS@#After an acclimation period, 32 male C57BL/6 mice were divided into the following groups: nonfat diet (NFD) vehicle, NFD supplemented, high-fat diet (HFD) vehicle and HFD supplemented. The vehicle and experimental formulation were administered orally by gavage once a day during the last four weeks of the diet (28 consecutive days). We then evaluated energy homeostasis, inflammation, and mitochondrial protein expression in these groups of mice.@*RESULTS@#After four weeks of supplementation, study groups experienced reduced glycemia, dyslipidemia, fat, and hepatic fibrosis levels. Additionally, proliferator-activated receptor-α, AMP-activated protein kinase-1α, peroxisome proliferator-activated receptor γ co-activator-1α, and mitochondrial transcription factor A expression levels were augmented; however, levels of inhibitor of nuclear factor-κB kinase subunit α and p65 nuclear factor-κB expression, and oxidative markers were reduced. Notably, the cortisol/C-reactive protein ratio, a well-characterized marker of the hypothalamic-pituitary-adrenal axis immune interface status, was found to be modulated by the supplement.@*CONCLUSION@#We discovered that the novel supplement was able to modify different antioxidant, metabolic and inflammatory pathways, improving the energy homeostasis and inflammatory status, and consequently alleviated hepatic steatosis.

Microbiota intestinal, prebióticos, probióticos e simbióticos em doenças gastrointestinais e hepáticas: procedimentos de reunião conjunta da Sociedade Brasileira de Hepatologia (SBH), Núcleo Brasileiro de Estudos do Helicobacter pylori e Microbiota (NBEHPM) e Federação Brasileira de Gastroenterologia (FBG) / Gut microbiota, prebiotics, probiotics, and synbiotics in gastrointestinal and liver diseases: proceedings of a joint meeting of the brazilian society of hepatology (sbh), brazilian nucleus for the study of helicobacter pylori and microbiota (nbehpm), and brazilian federation of gastroenterology (fbg)

ABSTRACT Over the last years, there is growing evidence that microorganisms are involved in the maintenance of our health and are related to various diseases, both intestinal and extraintestinal. Changes in the gut microbiota appears to be a key element in the pathogenesis of hepatic and gastrointestinal disorders, including non-alcoholic fatty liver disease, alcoholic liver disease, liver cirrhosis, inflammatory bowel disease, irritable bowel syndrome, and Clostridium difficile - associated diarrhea. In 2019, the Brazilian Society of Hepatology (SBH) in cooperation with the Brazilian Nucleus for the Study of Helicobacter Pylori and Microbiota (NBEHPM), and Brazilian Federation of Gastroenterology (FBG) sponsored a joint meeting on gut microbiota and the use of prebiotics, probiotics, and synbiotics in gastrointestinal and liver diseases. This paper summarizes the proceedings of the aforementioned meeting. It is intended to provide practical information about this topic, addressing the latest discoveries and indicating areas for future studies.

RESUMO Nos últimos anos, um volume crescente de evidências indica que os microrganismos estão envolvidos na manutenção da saúde humana e também estão relacionados a várias doenças, tanto intestinais quanto extraintestinais. Alterações na microbiota intestinal parecem ser um elemento chave na patogênese de doenças hepáticas e gastrointestinais, incluindo doença hepática gordurosa não-alcoólica, doença hepática alcoólica, cirrose hepática, doenças inflamatórias intestinais, síndrome do intestino irritável e diarreia associada ao Clostridium difficile. Em 2019, a Sociedade Brasileira de Hepatologia (SBH) em colaboração com o Núcleo Brasileiro para Estudo do Helicobacter pylori e Microbiota (NBEHPM) e a Federação Brasileira de Gastroenterologia (FBG) realizaram um encontro exclusivamente voltado para a discussão sobre microbiota e uso de prebióticos, probióticos e simbióticos em doenças hepáticas e gastrointestinais. Este texto resume os principais pontos discutidos durante o evento, e tem a intenção de fornecer informações práticas sobre o assunto, abordando as descobertas mais recentes e indicando áreas para estudos futuros.

Survival of commercial probiotic strains and their effect on dark chocolate synbiotic snack with raspberry content during the storage and after simulated digestion

BACKGROUND: A key challenge for manufacturers of pro-health food containing active probiotic microorganisms is to develop a product with attractive sensory features along with maintenance of declared number of microorganisms during storage and transfer by alimentary tract. RESULTS: The highest concentration of polyphenols was observed in snacks without an additive of probiotics as well as those with an additive of L. rhamnosus and B. animalis bacteria and concentration of these compounds increased by 9.5% during six months of storage. None of the products distinguished itself in the sensorial assessment although each was assessed positively. The number of microorganisms was stable and comparatively high during six months of storage at a room temperature and in cooling conditions (108 cfu/g). In the digestion model, an influence of aggressive digestion conditions was examined in the alimentary tract on the number of microorganisms, which allowed to arrange strains from the most resistant (S. boulardii) to the most sensitive (B. breve). It must be noted that currently on the market there is no available snack containing probiotic yeast as well as there is no literature data on works on such formulation of food. CONCLUSIONS: In the newly developed snack made of chocolate, in which sugar has been replaced with maltitol, a raw material was added in the form of raspberry, prebiotic in the form of inulin and a strain of probiotic bacteria, including the unprecedented so far S. boulardii, which stands a high chance to occupy a good place on the market of functional food.

Short-chain fatty acids production by Bifidobacterium species in the presence of salep

BACKGROUND: Salep is obtained by grinding dried orchid tubers and used as a valuable ingredient in the food industry. Because of the glucomannan content of salep, it is thought to have prebiotic potential. However, there is little information in studies concerning the fermentation characteristics and potential prebiotic properties of salep. The objective of this study was to investigate the effect of salep on bifidobacterial growth by measuring the highest optical density (OD), calculating the specific growth rates, and determining the production of lactic acid and short-chain fatty acids (acetic, propionic, and butyric acid) as a result of bacterial fermentation. RESULT: The OD and pH values obtained in this study showed that salep was utilized as a source of assimilable carbon and energy by the Bifidobacterium species (BS). All Bifidobacterium strains produced lactic, acetic, propionic, and butyric acid, indicating that salep is readily fermented by these bacteria. Salep at 1% (w/v) showed a similar effect on bifidobacterial growth as that promoted by 1% (w/v) glucose used as a traditional carbon source. CONCLUSIONS: Bifidobacterium species can develop in media containing salep as well as in glucose and exhibit the potential to be used as new sources of prebiotics.

Aportes de la biotecnología al diagnóstico y tratamiento de la enfermedad renal crónica y comorbilidades frecuentes / Biotechnology contribution to the diagnosis and treatment of chronic kidney disease and frequent comorbidities

Este trabajo tiene como objetivo revisar las contribuciones de la biotecnología, en relación con el tratamiento, diagnóstico y la monitorización de la enfermedad renal crónica (ERC) y sus comorbilidades más frecuentes, especialmente la anemia. En relación con los tratamientos, enfocamos el desarrollo de productos biofarmacéuticos como los agentes estimulantes de la eritropoyesis (ESA), que fueron los primeros biofármacos utilizados para el tratamiento de la anemia asociada a la ERC; analizamos sus características y utilización actual después de varios años de experiencia clínica, así como también otras alternativas en desarrollo. Revisamos distintos tipos de bioterapias, la utilización de las células estromales mesenquimales de médula ósea (MSC) y tratamientos alternativos con modificaciones dietarias, que se basan en la asociación entre la microbiota intestinal de los pacientes renales crónicos y sus condiciones fisiopatológicas. Finalmente, en relación con el diagnóstico y monitorización, nos referimos al estudio y validación de biomarcadores diagnósticos, predictivos y terapéuticos que han permitido optimizar los resultados clínicos en este tipo de pacientes. (AU)

The aim of this work is to review the contributions of biotechnology, in relation to the treatment, diagnosis and monitoring of chronic kidney disease (CKD) and its most frequent comorbidities, especially anemia. Regarding the treatment, we focus on the development of biopharmaceutical products such as erythropoiesis stimulating agents (ESA), which were the first biopharmaceuticals used to treat anemia associated with chronic kidney disease (CKD). We analyzed their characteristics and their current use after several years of clinical experience, as well as other alternatives in development. We also review different types of biotherapies, the use of bone marrow mesenchymal stromal cells (MSC) and alternative treatments with dietary modifications, which are based on the association between the intestinal microbiota of chronic kidney patients and their pathophysiological conditions. Finally, in relation to diagnosis and monitoring, we refer to the study and validation of diagnostic, predictive and therapeutic biomarkers that have made clinical results possible to be optimized in this type of patient. (AU)

Oligosacáridos y polisacáridos no digeribles: una fuente de salud para los adultos mayores / Non-digestible oligosaccharides and polysaccharides: a source of health for older people

RESUMEN Los adultos mayores son especialmente vulnerables a sufrir enfermedades asociadas al tracto gastrointestinal, ya que el envejecimiento conlleva naturalmente a un desbalance en la diversidad y cantidad de los microorganismos presentes en el intestino. Por ello, la suplementación de su dieta con oligosacáridos y polisacáridos no digestibles (OPND) ha cobrado gran relevancia científica. Esto, con el propósito de prevenir y revertir, en parte, los cambios negativos en la microbiota intestinal derivados del envejecimiento. Se ha observado que la suplementación de OPND en adultos mayores genera variados beneficios, entre los que destacan una mejora en el sistema inmune, una mayor absorción de calcio, reducción en la incidencia de alergias, reducción de la constipación y una disminución en los niveles de glicemia y colesterol sanguíneos. Debido a que, los efectos del consumo de OPND en adultos mayores han sido escasamente discutidos en la literatura científica en idioma castellano, el propósito de esta revisión es abordar el tema haciendo énfasis en la realidad chilena y latinoamericana. Ello, con miras a fomentar la incorporación de OPND en alimentos y programas de alimentación dirigidos específicamente a personas de la tercera edad.

ABSTRACT Since aging naturally leads to an imbalance in the diversity and quantity of microorganisms present in the intestine, older people are particularly vulnerable to diseases associated with the gastrointestinal tract. Thus, supplementing the diet of elderly persons with non-digestible oligosaccharides and polysaccharides (OPND) has gained scientific relevance. Supplementation aims to prevent and (partially) revert the negative changes in intestinal microbiota due to aging. It has been observed that OPND supplementation in older adults provides several benefits, including an improvement in the immune system, increased calcium absorption, a reduction in the incidence of allergies, a reduction in constipation and a decrease in blood levels of cholesterol and glucose. Because the effects of OPND supplementation in older adults has been scarcely discussed in the scientific literature in the Spanish language, the purpose of this review is to address the issue with emphasis on the Chilean and Latin-American reality. The article promotes the incorporation of OPND in processed food and feeding programs specifically designed for older people in Latin America.

Ecosistema intestinal en la infancia: rol de los "bióticos" / Gut ecosystem during infancy: The role of "biotics"

En los últimos años, las evidencias han demostrado la importancia de la microbiota intestinal en la salud del individuo. La dinámica de la colonización temprana y el establecimiento de una comunidad abundante y diversa de microorganismos saludables, a partir de un parto vaginal y lactancia materna, resultan fundamentales en la conformación de una matriz inmunológica saludable. Esta revisión tiene como objetivo describir las evidencias disponibles sobre el desarrollo de la microbiota en el primer año de vida y el actual potencial que ofrece el uso de prebióticos, probióticos, simbióticos y posbióticos durante esta etapa esencial de la vida

In recent years, the evidence has demonstrated the relevance of the gut microbiota in an individual's health. The dynamics of an early colonization and the establishment of a community of plenty, diverse, and healthy microorganisms from a vaginal delivery and breastfeeding are critical for the development of a healthy immune matrix. The objective of this review is to describe the available evidence on microbiota development in the first year of life and the current possibilities offered by prebiotics, probiotics, symbiotics, and postbiotics during such critical stage of life.

Prebiotics and butyric acid can replace colistin as a growth promoter for nursery piglets / [Prebióticos e ácido butírico podem substituir a colistina como promotor de crescimento para leitões em fase de creche]

This study aimed to assess different prebiotic concentrations and principles, in addition to calcium butyrate, aiming to replace colistin as a growth promoter. The sample consisted of 120 piglets weaned at 22 days old with mean initial weight of 5.475 ± 0.719kg. The animals were assigned to random blocks in six treatments corresponding to the use of the following dietary additives: T1) colistin (40 ppm); T2) ß-glucan/mannan-oligosaccharides (0.2%); T3) calcium butyrate (0.1%); T4) ß-glucan/mannan-oligosaccharides (0.1%) + fructooligosaccharides (0.01%) + galactooligosaccharides (0.09%); T5) ß-glucan/mannan-oligosaccharides (0.1%) + fructooligosaccharides (0.03%) + galactooligosaccharides (0.07%); and T6) ß-glucan/mannan-oligosaccharides (0.1%) + fructooligosaccharides (0.05%) + galactooligosaccharides (0.05%). The results showed no difference among treatments for the performance parameters in any of the phases evaluated. For diarrhea incidence and intensity, the results indicated that the treatments with alternative additives had similar effects as the group treated with colistin. A significant difference was found for the profile of propionic acid (0.23% colistin and 0.32%, 0.36%, 0.37% additives) and total fatty acids (0.67% colistin and 0.97% additives) values in the caecum. The supplementation with different compositions and concentrations of prebiotics and butyric acid may viably replace colistin in controlling diarrhea and modulating volatile fatty acid production in the caecum.(AU)

O objetivo deste trabalho foi avaliar as diferentes concentrações e princípios de prebióticos e do butirato de sódio, visando substituir a colistina como promotor de crescimento. Foram utilizados 120 leitões, desmamados aos 22 dias de idade, com peso médio inicial de 5,475 ± 0,719kg. Os animais foram distribuídos em blocos ao acaso, em seis tratamentos, que corresponderam ao uso dos seguintes aditivos dietéticos: T1) colistina (40ppm); T2) ß-glucanos/mananoligossacarídeos (0,2%); T3) butirato de cálcio (0,1%); T4) ß-glucanos/mananoligossacarídeos (0,1%) + frutoligossacarídeos (0,01%) + galactoligossacarídeos (0,09%); T5) ß-glucanos/mananoligossacarídeos (0,1%) + frutoligossacarídeos (0,03%) + galactoligossacarídeos (0,07%); e T6) ß-glucanos/mananoligossacarídeos (0,1%) + frutoligossacarídeos (0,05%) + galactoligossacarídeos (0,05%). Os resultados mostraram que não houve diferença entre os tratamentos para nenhum dos parâmetros de desempenho em nenhuma das fases avaliadas. Para a incidência e a intensidade de diarreia, os resultados apontam que os tratamentos com os aditivos alternativos apresentaram efeitos semelhantes aos do grupo tratado com colistina. Foi encontrada diferença significativa para perfil dos ácidos graxos propiônicos (0,23% colistina e 0,32%, 0,36%, 0,37% aditivos) e ácidos totais (0,67% colistina e 0,97% aditivos) no ceco. A suplementação com diferentes composições e concentrações de prebióticos e do ácido butírico pode substituir a colistina de forma viável no controle da diarreia e na modulação da produção volátil de ácidos graxos no ceco.(AU)

Eficácia da suplementação oral com 1, 3-1, 6 betaglucano proveniente de Saccharomyces cerevisiae no controle da mastite bovina / [Efficiency of oral supplementation of 1. 3-1. 6 beta-glucan from saccharomyces cerevisiae on the control of bovine mastitis]

A mastite bovina, uma das principais doenças do rebanho leiteiro, caracteriza-se por um processo inflamatório no úbere. A inviabilidade econômica, o impacto ambiental negativo e os resíduos antimicrobianos têm estimulado a pesquisa de outros tratamentos alternativos para a prevenção e o tratamento de doenças na bovinocultura leiteira. O betaglucano é um agente imunomodulador com potencial ação preventiva para doenças infecciosas, inclusive a mastite. Este estudo teve como objetivo avaliar a eficácia do uso do betaglucano, por meio de administração oral, em animais em lactação. Foram utilizadas 20 vacas lactantes, distribuídas em dois grupos, um controle e um tratamento, com 10 animais em cada grupo. O grupo tratamento recebeu 5g/dia, durante 60 dias, de 1,3-1,6 betaglucano isolado da parede celular de Saccharomyces cerevisiae diluído em ração após a ordenha, enquanto o grupo controle recebia somente a ração. Foram realizados os testes de California Mastitis Test (CMT), contagem de células somáticas (CCS), produção de leite e percentual de gordura e proteína no leite. Não houve diferença estatisticamente significativa entre os grupos quanto à CCS, ao CMT, à composição do leite ou produção. Não se observou, portanto, eficácia do uso do betaglucano purificado, administrado por via oral, no controle e na prevenção da mastite em vacas leiteiras, quando comparadas com o grupo controle. Atribuem-se esses resultados, principalmente, à degradação ruminal do produto testado. Sugerem-se, portanto, mais pesquisas utilizando o 1,3-1,6 betaglucano purificado de parede de S. cerevisiae por outras vias de administração, tais como intramamária e subcutânea.(AU)

Bovine mastitis, one of the main diseases of dairy herds, is characterized by an inflammatory process in the udder. The economic and environmental impacts, as well as the residues of antimicrobial drugs have stimulated the research of novel alternative treatments for the prevention and treatment of diseases in dairy production cows. The beta-glucan is an immunomodulator agent, with potential preventive action for infectious diseases, including mastitis. This study aimed to assess the effectiveness of orally administered beta-glucan in lactating cows. 20 lactating cows were used, distributed into two groups, one control and one treatment, with 10 cows in each group. The treatment group received 5g of 1.3-1.6 betaglucan daily for 60 days, isolated from the cell-wall of Saccharomyces cerevisiae diluted into a grain meal, whereas the animals in the control group received only the ration. The California Mastitis Test (CMT), Somatic Cells Counting (SCC), daily production and assessments of fat and protein content in milk were done. There was no statistically significant difference between the groups concerning subclinical mastitis detected by CMT, SCC, milk production and composition regarding protein and fat content. It was not observed, therefore, the effectiveness of the use of purified beta-glucan orally administered on the control or prevention of mastitis in dairy cows. The results are attributed to the ruminal degradation of the product tested. It is, therefore, suggested that more research should be conducted using the 1.3-1.6 beta-glucan purified from the cell wall of S. cerevisiae by other administration means and ruminal protection technologies for the isolated beta-glucan.(AU)

Uso de probióticos e/ou prebióticos na prevenção de eczema em crianças com alto risco de atopia: uma revisão sistemática / Probiotics and/or prebiotics use on the prevention of eczema in children with high risk of atopy: a systematic review

O objetivo deste estudo foi encontrar a relação do uso de probióticos e/ou prebióticos na prevenção do desenvolvimento de eczema atópico em crianças com alto risco. Foram utilizadas para esta revisão as bases de dados MEDLINE, via PubMed, SciELO e LILACS, com os seguintes descritores "(probiotics OR prebiotics) AND (allergy) AND (eczema)". Foram selecionados ensaios clínicos randomizados publicados até janeiro de 2020, sem restrição de idioma, em humanos, desde o nascimento até os 18 anos de idade. Foram recuperados 247 artigos, sendo cinco utilizados para análise. Quatro estudos não demonstraram relação entre o uso de probióticos e/ou prebióticos e a prevenção de eczema atópico em crianças de alto risco. Em contrapartida, um dos trabalhos obteve associação positiva, porém restrito a crianças com alergia à proteína do leite de vaca. Foi concluído nesta revisão que não existe relação entre o uso de probiótico e/ ou prebióticos em crianças de alto risco de atopia na prevenção de eczema, com possível exceção em crianças com alergia ao leite da vaca, com o desenvolvimento de eczema. É necessário a realização de mais estudos em longo prazo para a confirmação de real associação.

The aim of this study was to assess the relationship between the use of probiotics and/or prebiotics and the onset of eczema in children with high risk of atopy. PubMed, SciELO, and LILACS databases were used with the following descriptors: "(probiotics OR prebiotics) AND (allergy) AND (eczema)." Randomized clinical trials published up to January 2020, with no language restriction, involving humans from birth to 18 years of age were included. In total, 247 articles were found, and five were included in the analysis. Four trials did not show a relationship between the use of probiotics and/or prebiotics and the prevention of atopic eczema in high-risk children. In contrast, one clinical trial reported a positive association, but restricted to children with cow's milk allergy. In conclusion, there is no relationship between the use of probiotics and/or prebiotics and the onset of eczema in children with high risk of atopy, with a possible exception for children with cow's milk allergy. Additional long-term studies are necessary to confirm whether this association is true.

Nutritional influences on oral infections: the oral microbiota modulation

Introduction: The oral microbiota has approximately 700 symbiotic microorganisms responsible for oral health homeostasis. However, changes in oral microbiota can generate dysbiotic processes that favor the worsening of infections such as caries and periodontal disease. These oral infections, in addition to systemic involvement, can compromise the teeth integrity as well as oral health. Thus, inadequate nutrition proves to be a risk factor influencing the prevention and treatment of these oral infections. Objective: This study aims to evidence the nutritional influence on the oral microbiota modulation affecting, in the longterm, the gut microbiota, highlighting the use of probiotics and prebiotics in the treatment of oral infections by a literature review. Synthesis of data : Supplements of certain nutrients and the intake of an adequate diet in macronutrients and micronutrients directly influence nutritional status and consequently in the maintenance of oral-systemic homeostasis. In addition, due to microbial multidrug resistance, therapies using probiotics and prebiotics have been adopted as aids to the treatment of oral infections. Conclusion: Personalized Dentistry must integrate multidisciplinary knowledge of attention for health care. This in addition to knowingwhen to refer and work together with a Nutritionist.

Introdução: A microbiota oral possui aproximadamente 700 microrganismos simbiontes responsáveis pela homeostase da saúde bucal. Contudo, alterações na microbiota oral podem gerar processos disbióticos que favorecem o agravamento de infecções como a cárie e a doença periodontal. Essas infecções orais, além do acometimento sistêmico, podem comprometer a integridade dos dentes e também da saúde bucal. Dessa forma, a alimentação inadequada mostra-se um fator de risco que influência na prevenção e no tratamento dessas infecções orais. Objetivo: Este estudo visa evidenciar a influência nutricional na modulação da microbiota oral afetando a longo prazo a microbiota intestinal, destacando o uso de probióticos e prebióticos no tratamento de infecções orais através de uma revisão de literatura. Síntese de dados: A suplementação de determinados nutrientes e a ingestão de uma dieta adequada em macronutrientes e micronutrientes influenciam diretamente no estado nutricional e consequentemente na manutenção da homeostase oral-sistêmica. Além disso, devido à multirresistência microbiana, terapias com probióticos e prebióticos têm sido adotadas como auxiliares no tratamento de infecções orais. Conclusão: A Odontologia Personalizada deve integrar conhecimentos multidisciplinares de atenção à saúde. Isso além de saber quando encaminhar e trabalhar junto com o Nutricionista.

Fitoquímicos: una nueva clase de prebióticos / Phytochemicals: a new class of prebiotics

RESUMEN La microbiota intestinal (MI) es considerada como un nuevo blanco para la prevención y manejo nutricional de las alteraciones inflamatorias y metabólicas asociadas a las enfermedades crónicas no-transmisibles. Los prebióticos son principalmente fibras solubles cuyo consumo favorece el crecimiento de poblaciones bacterianas beneficiosas de la MI e impacta favorablemente la salud del consumidor. Esta revisión presenta a los fitoquímicos dietarios, que incluyen a más de 8.000 compuestos, como una nueva clase de prebióticos debido a su capacidad de estimular poblaciones de Lactobacillus, Bifidobacterium, Akkermansia y de bacterias productoras de butirato en el colon, a expensa de bacterias potencialmente dañinas como C. histolyticum. Además, los fitoquímicos son transformados por la MI en múltiples metabolitos que ejercen actividades biológicas a veces más potentes que la molécula inicial de la cual provienen. Individuos con distintos metabotipos han sido descritos de acuerdo a su capacidad de responder al consumo de isoflavonas, lignanos o elagitaninos, dependiendo de la presencia en su MI de bacterias capaces de transformar dichos polifenoles en equol, enterolactona/enterodiol y urolitinas, respectivamente, los cuales exhiben actividades biológicas. Valerolactonas y ácidos aromáticos también son producidos por la MI a través del metabolismo de las proantocianidinas. El efecto prebiótico de los fitoquímicos contribuiría a explicar los efectos saludables del consumo de frutas y verduras ricos en fitoquímicos.

ABSTRACT Intestinal microbiota (IM) is considered as a new target for the prevention and nutritional management of inflammatory and metabolic alterations associated with non-transmissible chronic diseases. Prebiotics are mainly soluble fibers whose consumption favors the growth of beneficial bacterial populations of the IM and positively impacts health. This review discusses dietary phytochemicals, which include more than 8,000 compounds, as a new class of prebiotics due to its ability to stimulate populations of Lactobacillus, Bifidobacterium, Akkermansia and butyrate producing bacteria in the colon at the expense of potentially harmful bacteria, such as C. histolyticum. In addition, phytochemicals are transformed by IM into a great array of metabolites exerting biological activities and are sometimes more potent than the initial molecule from which they are derived. Individuals with different metabotypes have been described according to their ability to respond to the consumption of isoflavones, lignans or ellagitannins, depending on the presence in their IM of bacteria capable of transforming these polyphenols into equol, enterolactone/enterodiol and urolithins, respectively, which exhibit biological activities. Valerolactones and aromatic acids are also produced by the IM through proanthocyanidin metabolism. The prebiotic effect of phytochemicals would help to explain the healthy effects associated with the consumption of fruits and vegetables rich in phytochemicals.

Efectos del uso de prebióticos y probióticos en la enfermedad de Alzheimer / Effects of the use of prebiotics and probiotics in alzheimer's disease

Introducción: la enfermedad de Alzheimer es la forma más común de demencia, la cual se asocia con el deterioro pro-gresivo de las funciones cognitivas; se caracteriza por la for-mación de ovillos neurofibrilares y placas seniles conformadas por la sustancia ß-amiloide. Desarrollo: el eje microbiota-intestino-cerebro permite la co-municación entre el tracto gastrointestinal y el cerebro. La micro-biota intestinal sufre modificaciones por el envejecimiento como el incremento de la permeabilidad intestinal y la translocación bacteriana. En presencia de disbiosis, los cambios en la motilidad y la secreción gastrointestinal alteran las células neuroendocrinas y del sistema inmune, y afectan la liberación de neurotransmiso-res. Así, las modificaciones de la microbiota pueden ocasionar la neuroinflamación que se observa en la enfermedad de Alzhei-mer. Los productos prebióticos y cepas de probióticos demostra-ron ser beneficiosos a nivel neurológico en dicha enfermedad, detectándose expresión de neurotransmisores y mejoría en las funciones cognitivas. Conclusiones: se ha documentado el uso de prebióticos y pro-bióticos en la enfermedad de Alzheimer, y se refirió que ocasio-nan reducción de la inflamación intestinal y disbiosis, así como mejora de las funciones cognitivas en estos pacientes. Sin em-bargo, en el tratamiento de la enfermedad de Alzheimer aún no se contempla el uso de los probióticos y tampoco se ha consi-derado como manera preventiva dado que las investigaciones son recientes.

Respuesta de las citocinas a la combinación de simbióticos y lactoferrina en recién nacidos de muy bajo peso al nacer: ensayo controlado aleatorizado / Cytokine responses to symbiotic and lactoferrin combination in very low birth weight neonates: a randomized control trial

Introducción. Los probióticos y prebióticos presentan beneficios potenciales en la inflamacióncrónica de las mucosas, incluida la prevención de la enterocolitis necrosante. No obstante, los mecanismos y resultados de estos efectos inmunomoduladores son confusos. El objetivo fue investigar la respuesta de las citocinas a Lactobacillus y Bifidobacterium asociados con fructo- y galactooligosacáridos (simbióticos) y lactoferrina en recién nacidos de muy bajo peso al nacer.Población y métodos. Se asignó aleatoriamente a lactantes con ≤32 semanas de gestación y ≤1500 g de peso para recibir simbióticos o 1 ml de agua destilada como placebo desde la primera alimentación hasta el alta. Se obtuvieron muestras de sangre los días posnatales 0 ± 2, 14 ± 2 y 28 ± 2, y se midieron interferón-γ, interleucina (IL)-5, IL-10 e IL-17A.Resultados. En el grupo del estudio (n = 25), la concentración de IL-10 disminuyó a lo largo del estudio (p = 0,011), pero no cambió en el grupo de referencia. La concentración de IL-5 se mantuvo constante los primeros 14 días y luego disminuyó significativamente (p= 0,042) en el grupo del estudio, mientras que aumentó en los primeros 14 días (p = 0,019) y luego disminuyó en 28 días (p = 0,011) en el grupo de referencia (n = 25).La concentración de otras citocinas no cambió a lo largo del estudio.Conclusión. El uso combinado de probióticos con oligosacáridos y lactoferrina estuvo asociado con una disminución en la concentración de IL-10, pero no se observó un cambio en las otras citocinas.

Introduction. Probiotics and prebiotics, which are multifunctional agents, have potential benefits in chronic mucosal inflammation, including the prevention of necrotizing enterocolitis. However, the mechanisms and the results of these immunomodulatory effects are not clear. This study aimed to investigate the cytokine response to the combination of Lactobacillus and Bifidobacterium together with fructo- and galacto-oligosaccharides (symbiotic) and lactoferrin in very low birth weight neonates.Population and Methods. Infants ≤ 32 GWs and ≤ 1,500 g were randomly assigned to receive a symbiotic combination or 1 ml distilled water as placebo starting with the first feed until discharge. Blood samples were obtained at postnatal 0 ± 2, 14 ± 2, and 28 ± 2 days, and the serum levels of interferon-γ, interleukin (IL)-5, IL-10, and IL-17A were measured.Results. In the study group (n = 25), the IL-10 levels decreased throughout the study period (p = 0.011) but did not change in the control group. The IL-5 levels remained steady in the first 14 days and decreased significantly thereafter (p = 0.042) in the study group, whereas they increased in the first 14 days (p = 0.019), and then decreased in 28 days (p = 0.011) in the control group (n = 25). The levels of the other cytokines did not change throughout the study period.Conclusion.The combined use of probiotics with oligosaccharides and lactoferrin was associated with a decrease in IL-10 levels, but no change was observed in the other cytokines.